Atrys Health SA (ES:ATRY) has released an update.
Atrys Health SA has reported a robust financial performance for the first nine months of 2024, with an adjusted EBITDA of €31.2 million, marking a 31.7% increase from last year. The company’s revenue surged to €155.6 million, driven by growth across all business lines, particularly in the Oncology segment and Latin American markets. This strong performance highlights Atrys’ effective operational strategies and cost-saving measures, positioning it as a leading player in the healthtech sector.
For further insights into ES:ATRY stock, check out TipRanks’ Stock Analysis page.
